The natural history of chronic allograft nephropathy.
By D. Goldfarb. Journal of Urology, 2005
1,099 citations recorded by the source corpus.
Subfields: Nephrology, Public Health, Environmental and Occupational Health, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/99a6e27d9153019c07f1f0e754cfb2e078811f67
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Public Health, Environmental and Occupational Health
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Calcineurin inhibitor nephrotoxicity. (2009, background): “Most commonly, global glomerulosclerosis results from severe CNI-associated arteriolar hyalinosis and arteriolopathy and secondary glomerular ischemia (115,155,156), as was also seen in diabetes mellitus (157).”
- Understanding the Causes of Kidney Transplant Failure: The Dominant Role of Antibody‐Mediated Rejection and Nonadherence (2012, background): “Some have postulated that late deterioration reflects dysregulated fibrosis, drug toxicity (3) or progressive “chronic allograft nephropathy” (3–5), although this term has been dismissed by the Banff pathology consensus because it does not represent a specific disease entity (6).”
- Identifying Specific Causes of Kidney Allograft Loss (2009, result): “Also, in contrast to other studies (26), but in agreement with others (12), these results do not identify calcineurin inhibitor toxicity as a frequent cause of kidney allograft failure.”
- Rational Development of LEA29Y (belatacept), a High‐Affinity Variant of CTLA4‐Ig with Potent Immunosuppressive Properties (2005, background): “Histological evidence of calcineurin-inhibitorassociated nephrotoxicity is essentially universal in renal transplants by 10 years (25).”
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing (2015, background): “3 mg/kg/day, followed by TDM, given the risk of arterial vasoconstriction, hypertension, and nephrotoxicity that can occur with supratherapeutic tacrolimus concentrations.(15,16) In addition, concomitant medications, abnormal liver function, or presence of clinical conditions, such as diarrhea, must”
- Identification of a B cell signature associated with renal transplant tolerance in humans. (2010, background): “1% (1) Systemic lupus erythematosus – – 9.”
- A Phase III Study of Belatacept‐based Immunosuppression Regimens versus Cyclosporine in Renal Transplant Recipients (BENEFIT Study) (2010, background): “ity margin and (4) the superiority test on chronic allograft nephropathy at”